Phase II study of a modified combination of etoposide, doxorubicin, and cisplatin for patients with advanced gastric

Icli F., Karaoguz H., AKBULUT H., Dincol D., DEMİRKAZIK A., Cay F.

JOURNAL OF SURGICAL ONCOLOGY, cilt.64, sa.4, ss.318-323, 1997 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 64 Sayı: 4
  • Basım Tarihi: 1997
  • Dergi Adı: JOURNAL OF SURGICAL ONCOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.318-323
  • Anahtar Kelimeler: etoposide, doxorubicin, cisplatin, chemotherapy, advanced gastric cancer, COOPERATIVE-ONCOLOGY-GROUP, CANCER, CHEMOTHERAPY, TRIAL, ADRIAMYCIN, EAP, ADENOCARCINOMA, CARCINOMA
  • Lokman Hekim Üniversitesi Adresli: Hayır

Özet

Background: Based on the promising results of EAP (etoposide, doxorubicin, and cisplatin) combination, a phase II study of modified EAP combination was performed in patients with advanced gastric cancer to evaluate the response, toxicity, and survival.